WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL - Chee Kay Cheung; Stephanie Moody; Neeraj Dhaun; Siân Griffin; Alexandra Howson; Alex Mercer; Matthew Sayer; Smeeta Sinha; Lisa Willcocks; Jonathan Barratt (Kidney International Reports)